AstraZeneca says Imfinzi and Imdelltra improved survival
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival for extensive-stage small-cell lung cancer patients in a late-stage trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AstraZeneca says Imfinzi plus Imdelltra improved survival in SCLC
AstraZeneca PLC said Imfinzi plus Imdelltra showed statistically significant and highly clinically meaningful improvements in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer.